Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Olivia Brayer is an analyst at Cantor Fitzgerald. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/01/2024
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 07/01/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $243.32 | -38.35% | $150 → $150 | Reiterates | Neutral → Neutral | Get Alert |
| 05/09/2024 | MNKD | Buy Now | MannKind | $5.10 | 27.45% | → $6.5 | Reiterates | Overweight → Overweight | Get Alert |
| 05/03/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $1.06K | -12.49% | → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 04/25/2024 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.13 | 33.93% | → $110 | Reiterates | Overweight → Overweight | Get Alert |
| 04/17/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $1.06K | -12.49% | → $925 | Reiterates | Neutral → Neutral | Get Alert |
| 03/15/2024 | MNKD | Buy Now | MannKind | $5.10 | 27.45% | → $6.5 | Reiterates | Overweight → Overweight | Get Alert |
| 02/28/2024 | MNKD | Buy Now | MannKind | $5.10 | 27.45% | → $6.5 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.13 | 21.76% | → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.49 | 82.15% | $12 → $10 | Maintains | Overweight | Get Alert |
| 02/23/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $243.32 | -38.35% | $165 → $150 | Maintains | Neutral | Get Alert |
| 02/20/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -6.63% | → $440 | Reiterates | Overweight → Overweight | Get Alert |
| 02/20/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $243.32 | -32.19% | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/15/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $243.32 | -32.19% | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/12/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $243.32 | -32.19% | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/07/2024 | GILD | Buy Now | Gilead Sciences | $68.56 | 13.78% | $80 → $78 | Maintains | Neutral | Get Alert |
| 02/06/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -6.63% | → $440 | Reiterates | Overweight → Overweight | Get Alert |
| 02/06/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $1.06K | -12.49% | $850 → $925 | Maintains | Neutral | Get Alert |
| 01/24/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -6.63% | $415 → $440 | Maintains | Overweight | Get Alert |
| 01/22/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $243.32 | -32.19% | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 01/18/2024 | ALNY | Buy Now | Alnylam Pharmaceuticals | $243.32 | -32.19% | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 01/12/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -11.94% | → $415 | Reiterates | Overweight → Overweight | Get Alert |
| 01/09/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -11.94% | → $415 | Reiterates | Overweight → Overweight | Get Alert |
| 01/09/2024 | REGN | Buy Now | Regeneron Pharmaceuticals | $1.06K | -19.59% | → $850 | Reiterates | Neutral → Neutral | Get Alert |
| 12/14/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -19.36% | → $380 | Reiterates | Overweight → Overweight | Get Alert |
| 12/14/2023 | ALNY | Buy Now | Alnylam Pharmaceuticals | $243.32 | -32.19% | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 12/05/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -19.36% | → $380 | Reiterates | Overweight → Overweight | Get Alert |
| 11/16/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -19.36% | → $380 | Reiterates | Overweight → Overweight | Get Alert |
| 11/15/2023 | BMY | Buy Now | Bristol-Myers Squibb | $41.35 | 33.01% | $68 → $55 | Downgrade | Overweight → Neutral | Get Alert |
| 11/07/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -19.36% | $370 → $380 | Maintains | Overweight | Get Alert |
| 11/02/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.13 | 21.76% | $120 → $100 | Maintains | Overweight | Get Alert |
| 10/16/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.13 | 46.11% | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 10/16/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -21.49% | → $370 | Reiterates | Overweight → Overweight | Get Alert |
| 10/16/2023 | ALNY | Buy Now | Alnylam Pharmaceuticals | $243.32 | -30.13% | $190 → $170 | Maintains | Neutral | Get Alert |
| 10/09/2023 | BMY | Buy Now | Bristol-Myers Squibb | $41.35 | 81.38% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 09/15/2023 | BMY | Buy Now | Bristol-Myers Squibb | $41.35 | 81.38% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 09/14/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.13 | 46.11% | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 09/14/2023 | ALNY | Buy Now | Alnylam Pharmaceuticals | $243.32 | -21.91% | → $190 | Reiterates | Neutral → Neutral | Get Alert |
| 09/13/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.13 | 46.11% | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 09/07/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -21.49% | → $370 | Reiterates | Overweight → Overweight | Get Alert |
| 08/16/2023 | ALNY | Buy Now | Alnylam Pharmaceuticals | $243.32 | -21.91% | → $190 | Reiterates | Neutral → Neutral | Get Alert |
| 08/08/2023 | MNKD | Buy Now | MannKind | $5.10 | 47.06% | $6.5 → $7.5 | Maintains | Overweight | Get Alert |
| 08/02/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -21.49% | $365 → $370 | Reiterates | Overweight → Overweight | Get Alert |
| 08/01/2023 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.13 | 46.11% | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 07/24/2023 | GILD | Buy Now | Gilead Sciences | $68.56 | 16.69% | → $80 | Reiterates | Neutral → Neutral | Get Alert |
| 07/20/2023 | GILD | Buy Now | Gilead Sciences | $68.56 | 16.69% | $85 → $80 | Maintains | Neutral | Get Alert |
| 07/20/2023 | BMY | Buy Now | Bristol-Myers Squibb | $41.35 | 105.56% | $88 → $85 | Maintains | Overweight | Get Alert |
| 07/13/2023 | ALNY | Buy Now | Alnylam Pharmaceuticals | $243.32 | -17.8% | → $200 | Reiterates | Neutral → Neutral | Get Alert |
| 07/12/2023 | ALNY | Buy Now | Alnylam Pharmaceuticals | $243.32 | -17.8% | → $200 | Reiterates | Neutral → Neutral | Get Alert |
| 07/06/2023 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.49 | 173.22% | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 06/23/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -22.55% | $365 → $365 | Reiterates | Overweight → Overweight | Get Alert |
| 06/23/2023 | ALNY | Buy Now | Alnylam Pharmaceuticals | $243.32 | -17.8% | $200 → $200 | Reiterates | Neutral → Neutral | Get Alert |
| 06/22/2023 | ALNY | Buy Now | Alnylam Pharmaceuticals | $243.32 | -17.8% | → $200 | Reiterates | Neutral → Neutral | Get Alert |
| 05/30/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -22.55% | → $365 | Reiterates | Overweight → Overweight | Get Alert |
| 04/13/2023 | CRSP | Buy Now | CRISPR Therapeutics | $53.89 | 33.61% | → $72 | Initiates | → Overweight | Get Alert |
| 02/23/2023 | GRPH | Buy Now | Graphite Bio | — | — | $56 → $21 | Downgrade | Overweight → Neutral | Get Alert |
| 01/17/2023 | BMY | Buy Now | Bristol-Myers Squibb | $41.35 | 129.75% | → $95 | Initiates | → Overweight | Get Alert |
| 09/15/2022 | GRPH | Buy Now | Graphite Bio | — | — | → $84 | Initiates | → Overweight | Get Alert |
| 07/13/2022 | BMRN | Buy Now | Biomarin Pharmaceutical | $82.13 | 33.93% | → $110 | Initiates | → Overweight | Get Alert |
| 07/13/2022 | GILD | Buy Now | Gilead Sciences | $68.56 | 2.11% | → $70 | Initiates | → Neutral | Get Alert |
| 07/13/2022 | VRTX | Buy Now | Vertex Pharmaceuticals | $471.25 | -22.55% | → $365 | Initiates | → Overweight | Get Alert |
| 07/13/2022 | ALNY | Buy Now | Alnylam Pharmaceuticals | $243.32 | -28.08% | → $175 | Initiates | → Neutral | Get Alert |
| 05/05/2022 | AUPH | Buy Now | Aurinia Pharmaceuticals | $5.49 | 355.37% | → $25 | Assumes | → Overweight | Get Alert |
